Torthaí cuardaigh - Emilio Alba

Beachtaigh na torthaí
  1. 1
    Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer

    Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer de réir Ana R. Quesada, Miguel Ángel Medina, Emilio Alba

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer

    The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer de réir Nuria Ribelles, Ángela Santonja, Bella Pajares, Casilda Llácer, Emilio Alba

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study

    Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study de réir Antonio Rueda‐Domínguez, A. Márquez, Josep Gumà, Marta Llanos, J. Herrero, M Nieves, José Miramón, Emilio Alba

    Foilsithe / Cruthaithe 2004
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review

    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review de réir Jesús García‐Foncillas, Emilio Alba, Enrique Aranda, Eduardo Díaz‐Rubio, Rafael López‐López, Josep Tabernero, Ana Vivancos

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Bevacizumab–Capecitabine (BEV–CAP) After Initial 1st-Line Bevacizumab–Docetaxel (BEV–DOC) in Patients (PTS) With HER2-Negative Metastatic Breast Cancer (MBC): Safety Analysis of the IMELDA Trial

    Bevacizumab–Capecitabine (BEV–CAP) After Initial 1st-Line Bevacizumab–Docetaxel (BEV–DOC) in Patients (PTS) With HER2-Negative Metastatic Breast Cancer (MBC): Safety Analysis of th... de réir Joseph Gligorov, Emilio Alba-Conejo, José Bines, P. Cortes, Dinesh Doval, Zefei Jiang, Ulrich Freudensprung, Giorgio Mustacchi

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications

    Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications de réir Ana Godoy-Ortiz, Alfonso Sánchez‐Muñoz, M Rosario Chica Parrado, Martina Álvarez, Nuria Ribelles, Antonio Rueda‐Domínguez, Emilio Alba

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response

    Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response de réir Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel‐Ángel Berciano‐Guerrero, Emilio Alba, Manuel Cobo, Volker M. Lauschke, Isabel Barragán

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

    Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer de réir Alfonso Sánchez‐Muñoz, Elena Gallego, Vanessa de Luque, Luis Gustavo Perez‐Rivas, Luís Vicioso, Nuria Ribelles, José Lozano, Emilio Alba

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Efficacy and Safety of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) After Initial First-Line Bev Plus Docetaxel (Doc) for Her2-Negative Metastatic Breast Cancer (Mbc): Imelda Randomised Phase III Trial

    Efficacy and Safety of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) After Initial First-Line Bev Plus Docetaxel (Doc) for Her2-Negative Metastatic Breast Cancer... de réir Joseph Gligorov, D.C. Doval, José Bines, Z. Jiang, Emilio Alba, P. Cortes, Stefanie Srock, Sabine de Ducla, Ulrich Freudensprung, Giorgio Mustacchi

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients

    GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients de réir Victoria Contreras-Bolívar, Francisco José Sánchez-Torralvo, María Dolores Martínez Ruíz, Inmaculada González-Almendros, Manuel Barrios, Susana Padín, Emilio Alba, Gabriel Olveira

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Challenges and achievements of liquid biopsy technologies employed in early breast cancer

    Challenges and achievements of liquid biopsy technologies employed in early breast cancer de réir Alfonso Alba-Bernal, Rocío Lavado-Valenzuela, María Emilia Domínguez-Recio, Begoña Jiménez-Rodríguez, María Isabel Queipo‐Ortuño, Emilio Alba, Iñaki Comino‐Méndez

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study

    Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast... de réir Emilio Alba, Miguel Martín, Manuel Ramos, Encarna Adrover, A. Balil, Carlos Jara, Agustí Barnadas, António Fernández, Pedro Sánchez‐Rovira, Margarita Amenedo, Antonio Casado

    Foilsithe / Cruthaithe 2004
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic... de réir Sunil Verma, Joyce O’Shaughnessy, Howard A. Burris, Mario Campone, Emilio Alba, David Chandiwana, Anand A. Dalal, Santosh Sutradhar, Mauricio Monaco, Wolfgang Janni

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment

    Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment de réir Aurora Laborda-Illanes, Lidia Sánchez‐Alcoholado, María Emilia Domínguez-Recio, Begoña Jiménez-Rodríguez, Rocío Lavado-Valenzuela, Iñaki Comino‐Méndez, Emilio Alba, María Isabel Queipo‐Ortuño

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression

    A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression de réir Nuria Ribelles, J. Lopez-Siles, A. Bartolomé Sánchez, Emilio Esteban, María‐José Sánchez, F. Carabantes, P. Sanchez-Rovira, A. Márquez, Rosario Dueñas, Isabel Sevilla, Emilio Alba

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    A microRNA Signature Associated with Early Recurrence in Breast Cancer

    A microRNA Signature Associated with Early Recurrence in Breast Cancer de réir Luis Gustavo Perez‐Rivas, José M. Jerez, Rosario Carmona, Vanessa de Luque, Luís Vicioso, M. Gonzalo Claros, Enrique Viguera, Bella Pajares, Alfonso Sánchez, Nuria Ribelles, Emilio Alba, José Lozano

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines de réir Denis Talbot, Vladimir Moiseyenko, Simon Van Belle, S.M. O'Reilly, Emilio Alba, Stephen P. Ackland, Peter D. Eisenberg, David Melnychuk, Tadeusz Pieńkowski, H-U Burger, Siobhan Laws, B Osterwalder

    Foilsithe / Cruthaithe 2002
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer: the EarLEE adjuvant clinical trials program

    The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer: the EarLEE adjuvant clinical trials progra... de réir Michelino De Laurentiis, Filippo Montemurro, Thomas Bachelot, Miguel Martín, C.H. Barrios, Bella Kaufman, Peter Schmid, Emilio Alba, Véronique Dièras, S. Mondal, A. Chakravartty, Mark Shilkrut, Michelle C. Miller, Michael Untch

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer

    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer de réir Iñaki Comino‐Méndez, Jesús Velasco-Suelto, Javier Pascual, Esperanza López-López, María Elena Quirós-Ortega, Celia Gaona-Romero, Alejandro Martín-Muñoz, Patricia Losana, Yanira Heredia, Emilio Alba, Ángel Guerrero‐Zotano

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study

    Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study de réir Nuria Ribelles, Javier Pascual, Laura Gálvez, Sofía Ruiz-Medina, Javier Garcia-Corbacho, José Carlos Benítez, María Emilia Domínguez-Recio, Esperanza Torres, L. Martinez Oliva, Manuel Zalabardo-Aguilar, Antonio Rueda, Emilio Alba

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: